Fonds de solidarité FTQ discloses $13.4 mln Clementia financing

Fonds de solidarité FTQ has disclosed a March 2017 investment in Clementia Pharmaceuticals Inc, a Montréal clinical-stage biopharmaceutical company. The investment provided Clementia with about $13.4 million (US$10 million) in funding. Fonds de solidarité FTQ also said it is participating in the company's initial public offering, which was priced this week to raise as much as $172 million (US$138 million). Clementia, which was launched in 2010, is developing treatments for patients suffering from debilitating bone and other diseases.

CanadaNorth AmericaBriefs